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Abstract
Background: Cancer is one of the devastating neovascular diseases that incapacitate so many
people the world over. Recent reports from the National Cancer Institute indicate some significant
gain therapy and cancer management as seen in the increase in the 5-year survival rate over the
past two decades. Although near-perfect cure rate have been reported in the early-stage disease,
these data reveal high recurrence rate and serious side effects including second malignancies and
fatalities. Most of the currently used anticancer agents are only effective against proliferating cancer
cells. Thus attention has been focused on potential anti-cancer agents capable of killing cancer cells
independent of the cell cycle state, to ensure effective elimination of most cancer cells. The
objective of this study was to test the chemosensitivity and potential mechanism of action of a novel
cancer drug, CytoregR, in a panel of human cancer cells.
Methods: the study was performed using a series of bioassays including Trypan blue exclusion,
MTS Growth inhibition, LDH-cytotoxicity, TUNEL-Terminal DNA fragmentation Apoptosis Assay,
and the Caspase protease CPP32 activity assays.
Results: CytoregR induced significant dose- and time-dependent inhibition of growth in all the cells;
with significant differences in chemosensitivity (P < 0.05) between the target cells becoming more
apparent at 48 hr exposure. CytoregR showed no significant effect on normal cells relative to the
tumor cells. Growth inhibition in all the cells was due to induction of apoptosis at lower
concentrations of cytoregR (> 1:300). CytoregR-induced caspase protease-3 (CPP32) activation
significantly and positively correlated with apoptosis induction and growth inhibition; thus
implicating CPP32 as the principal death pathway in cytoregR-induced apoptosis.
Conclusion: CytoregR exerted a dose-and time-dependent growth inhibitory effect in all the
target cells through induction of apoptosis via the CPP32 death pathway, independent of hormonal
sensitivity of the cells. The present data indicate that not only could CPP32 provide a potential
target for regulation of cytoregR-induced apoptosis but also that cytoregR could play a significant
role in chemotherapeutic regimen in many human malignant tumors.
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Introduction
Cancer is one of the devastating neovascular diseases that
incapacitate so many people the world over. It is one of
the top leading causes of death in the western world. Con-
tinuous search for cure and prevention over the past years
seems to be yielding encouraging results and this gives the
impetus for further search for effective therapeutic regi-
mens against this unyielding human and animal diseases.
Significant Progress in the fight against human cancer has
been made since the early 1960s. Recent reports from the
National Cancer Institute [1] and American Cancer Soci-
ety [2] indicate some significant gain over the scorch of
cancer as seen in the increase in the 5-year survival rate
over the past two decades. The overall cancer incidence
rates dropped 0.5 percent per year from 1991 to 2001,
while death rates from all cancers combined dropped 1.1
percent per year from 1993 to 2001 [1]. Death rates from
all cancers combined have been decreasing since the early
1990s. Death rates decreased for 11 of the top 15 cancers
in men, and eight of the top 15 cancers in women. Lung
cancer deaths rates among women leveled off for the first
time between 1995 and 2001, after continuously increas-
ing for many decades [1]. This year's report indicate that
between the periods 1975–1979 and 1995–2000 the five-
year cancer survival rate improved for most of the top 15
cancers in both men and women, and the top ten sites in
children [1]. However, the incidence rate of Breast cancer
in women is among the cancers that are still rising. And in
men, although significant gains are made in the survival
rates in many cancers including the prostate, the incidence
rate in prostate cancer is rising [1]. Furthermore, the inci-
dence of testicular cancer has increased three-folds over
the past 40 years especially in the Caucasian young males
in the 15 to 35-age range [3-5], in spite of high sensitivity
of this cancer to treatment. The risk of developing testicu-
lar cancer in a man's lifetime is approximately 1 in 500
occurring in approximately 1 in 25,000 men per year [2].
Testicular cancer is 4 times more common in Caucasians
than in Afro-American men, with intermediate incidence
rates among Native Americans, Hispanics and Asians
[6,7]. It is the third (14.3% of all male cancers) most com-
monly diagnosed cancer among males aged 15–19 years
[8]. Testicular cancer has shown the highest cure rates of
all human cancers. Most cancer patients, especially those
diagnosed at the early stage, can now expect to survive the
disease [9,10]. Satisfactory survival rate is being achieved
in advanced metastatic disease by the use of multidiscipli-
nary therapeutic approach [9,11]. Although near-perfect
cure rate with chemotherapy have been reported in early-
stage disease [10], these results reveal high recurrence rate,
serious side effects [11-13], and disease progression (sec-
ond malignancies) and treatment-induced fatalities.
Most of the currently used anticancer agents are only effec-
tive against proliferating cancer cells [22]. This partially
accounts for the high post-treatment recurrence rate of tes-
tis cancer. Currently, attention is being focused on poten-
tial anti-cancer agents capable of inducing apoptosis cell
death independent of the cell cycle state, to ensure effec-
tive elimination of all/most cancer cells. One such reagent
of interest is the novel drug, cytoregR
Cytoreg® is a novel anticancer drug candidate which uses
hydrofluoric and sulfuric acids as active compounds. The
product is a pharmacologically active low pH acid mixture
(pH < 1.0) of which hydrofluoric acid (HF) and sulfuric
acid (H2SO4) are active principles. The fluoride ion in
cytoreg induces the synthesis of interleukins-1 and 6 (IL-
1, IL-6), tumor necrotic factor alpha (TNFα), and stimu-
lating factors of macrophages and granulocytes. IL-1 acti-
vates T cells and other cytokines. IL-1 is known to be
chemo-protective and radiosensitive, protecting animals
against myelosuppression. Cytorex is focused on develop-
ingcompounds to treat cancer and immunological-based
diseases. Cytorex has world wide intellectual property
rights to Cytoreg® and CytoregUNO™ [30].
Cytoreg® has demonstrated anticancer activity in a battery
human cancer cells in in vitro studies in our laboratory,
and limited preliminary pre-clinical studies elsewhere.
Several preliminary in vitro studies in our laboratory indi-
cate that cytoregR inhibits growth and proliferation
through induction of apoptosis in a battery of human can-
cer cells. In this study we hypothesized that the cytoregR
will induce growth inhibition of human prostate, breast
and testis cancer cells through induction of apoptosis. The
goal of this study was to assess degree of potential chem-
osensitivity of cytoregR to these cancer cells and mecha-
nism of action of the drug in the target cells.
Materials and methods
Chemicals
Culture media (RPMI 1640 complete), antibiotics, fetal
bovine serum (FBS), trypsin-EDTA, and other culture
materials were purchased from Sigma Scientific (St. Louis,
MO, USA). The caspase kit (Ac-DEV-AFC/z-VAD-fmk) was
from Geno Tech Inc. St. Louis MO.
Test agents
Cytoreg® was supplied by Cytorex Biosciences, Inc.
Cell lines
GI-101, an estrogen-independent metastatic human
breast cancer cells, was obtained from Rambaugh-Good-
win Cancer Research institute (RGI) at Plantation FL;
MCF-7, estrogen-dependent breast cancer cells, were ini-
tially obtained from the American Type Culture Collec-
tion (ATCC) and maintained in our laboratory; PC3,
androgen-dependent human prostate adenocarcinoma
cells, were originally obtained from the ATCC and main-Journal of Carcinogenesis 2006, 5:1 http://www.carcinogenesis.com/content/5/1/1
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tained in our laboratory. Other human cancer cells origi-
nally obtained from ATCC were: LNCaP, androgen-
independent adenocarcinoma of the prostate; INTERA-2
cl.D1, androgen-dependent human adenocarcinoma cells
of the testis; and Hs 1.Tes, normal human testis cell lines
(nPL) Normal primary human placenta cells were a cour-
tesy of Prof Manzur Hassanhi (Medical School at Univer-
sity of Zulia, Maracaibo Venezuela). All cells were cultured
and maintained in humidified atmosphere at 37°C and
5% CO2 in RPMI1640 medium supplemented with 10%
bovine fetal serum (FBS), 2 mM glutamine and 100 U/mL
of penicillin + 100 mg/mL of streptomycin (Sigma, St.
Louis, MO. USA).
Culturing and drug treatment of cells
Cells were plated/dispensed into wells of 96-well micro-
titer plates (MTP) at a concentration of 2 × 103 cells/well
in 100 µl volumes, and incubated for 48 hrs at 37°C in a
humidified atmosphere containing 5% CO2  to allow
adherence, prior to exposure to varying concentrations/
dilutions of cytoregR (2000, 1000, 500, 200, 100, 50 dilu-
tions; the highest dilution being the lowest exposure con-
centration, and the lowest dilution being the highest
exposure concentration). Briefly, the cells were treated
with the predetermined concentrations in triplicates and
cultured/grown in humidified atmosphere at 37°C and
5% CO2 for up to 48 hr. post-treatment. After the 48 hr
incubation, the supernatants were collected and frozen for
lactate dehydrogenase (LDH) determination; the adher-
ent cells were evaluated for post-treatment viability using
Trypan blue exclusion and MST assays. Information on
cell numbers relative to controls was important in order to
determine whether cytoregR was toxic or simply slowing
or inhibiting cell replication. The TUNEL assay was used
to determine treatment-induced apoptosis in the cells;
and Caspase-3 protease involvement in the cytoregR-
induced apoptosis was evaluated as described below: The
experiment was repeated twice with the same dose ranges
to quantify growth inhibitory activity.
MTS growth inhibition assay
MTS is a calorimetric assay based on the ability of viable
cells to convert MTS to formazan; the quantity of forma-
zan product, as measured by 490 nm absorbance is
directly proportional to the number of viable cells in cul-
ture. Briefly, at the end of the 48 hr incubation period
with the drugs as described above, 100 µl of the growth
medium was removed. The cells were then incubated with
20 µl MTS tetrazolium compound for 3 hr at 37°C. Dur-
ing the incubation the MTS salt is metabolically reduced
only by viable cells into an insoluble colored formazan;
and the absorbance/optical density (OD) was read and
recorded on a Multiscan ELISA MTP reader at a single
wavelength of 490 nm. The data were presented as percent
post-treatment recovery (%live cells) where the absorb-
ance of from the control, non-treated cells was defined as
100% live cells. The % recovery (%Live cells) were
graphed (Y-axis) against the concentrations (X-axis)
where IC50 values could be interpolated from the graph.
LDH-cytotoxicity assay
Lactate dehydrogenase activity was measured by a non-
radioactive protocol using the LDH cytotox kit (Cat. #.
1644 793: Boehringer-Mannheim GmbG, Bochemica).
Test principle: The LDH assay is based on the release of the
cytosol enzyme, lactate dehydrogenase (LDH) from cells
with damaged cellular membranes. Thus in cell culture,
the course of drug-induced cytotoxicity can be followed
quantitatively by measuring the activity of LDH in the
supernatant. Methodology: The previously frozen super-
natants were thawed for LDH determination. Briefly, 100
µL/well of each cell-free supernatant was transferred in
triplicates into wells in a 96-well microtiter plates (MTP)
and 100 µL of LDH-assay reaction mixture (Kit: dye-cata-
lyst mixture) added to each well. After 3 hr incubation
under standard conditions of 37°C 5% CO2, the absorb-
ance/optical density of the color generated was read on
Multiskan biochromatic automatic microplate reader at
490 nm. Percentage treatment-induced cytotoxicity was
computed as follows:
Where, ODt = mean optical density of treated cells; ODc =
mean optical density of controls without treatment.
%Cytotoxicity
OD OD
OD OD
tc
tc
=
−
−
×100
Table 1: Effect of cytoregR on cancer cells at the dilution of 1:500 (pH7.1) and 48 hr incubation/exposure
Assays PC3 LNCaP MCF-7 GI-101 nPL NTERA-
2CL.DI
Hs1.Tes
T/blue 44.06(6.5)a 51.08(7.9)b 51.08(8.3)b 61.01(11.6)c 81.89(13.5)e 22.08(3.9)f 77.56(13.7)e
MTT 59.25(10.8)a 45.85(6.6)b 60.88(11.1)a 65.12(13.2)c 81.89(14.7)d 37.57(5.5)e 79.25(12.9)d
LDH 0.167(.03)a 0.196(.07)b 0.175(.04)c 0.193(.07)b 0.061(.01)e 0.125(0.06)f 0.073(0.01)g
%apopt 49.19(8.8)a 60.76(11.7)b 53.15(9.5)c 45.59(7.4)a 8.05(0.75)d 52.25(7.9)c 9.15(1.9)e
%CPP32 35.04(4.9)a 41.08(5.8)b 37.35(6.6)a 28.85(6.1)c 9.56(0.93)d 33.65(4.5)a 11.06(2.3)d
% apopt = % apoptosis; %CPP32 = %caspase-3 protease; T/blue = Trypan blue exclusion assay.
Numbers in brackets () are standard errors of means (SEM): Rows with different superscripts are statistically different (P < 0.01)Journal of Carcinogenesis 2006, 5:1 http://www.carcinogenesis.com/content/5/1/1
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The ODs were graphed (Y-axis) against the concentrations
(X-axis) and the IC50 values interpolated from the graph
TUNEL-Terminal DNA fragmentation apoptosis assay
The presence of apoptosis was determined by terminal
deoxynucleotidyl transferase (TdT)-mediated dUTP nick
end labeling (TUNEL), using the ApopTagR  kit (Boe-
hringer Mannheim Co, Indianapolis, IN) as previously
described (14). The kit reagents detect apoptotic cells in
situ by specific end labeling and detection of DNA frag-
ments produced by the apoptotic process. Briefly, cells
were suspended in phosphate buffered saline (PBS) and
aliquots were first pre-stained with supra-vital propidium
iodide (PI) stain, and examined under fluorescence
microscope to differentiate between apoptosis (PI nega-
tive) and necrosis (PI positive), according to previously
described procedure [15]. To perform the TUNEL assay,
slides were prepared with aliquots from the PBS-cell sus-
pensions. The cells (slides) were then permeabilized with
Triton X-100 at 4°C for 2 min; then flooded with TdT
enzyme and digoxigenin-dUTP reaction buffer (TUNEL)
reagent for 60 min at 37°C; followed by further incuba-
tion in anti-fluorescein antibody Fab (conjugated with
alkaline phosphatase). After this the cells were stained
with chromogenic substrate (Fast Red) and mounted.
Negative controls were performed by substituting distilled
water for TdT enzyme in the preparation of working solu-
tions. The stained mounted cells were examined at 100×,
200× and 400× magnification of the microscope (Olym-
pus BH-2). Cell death was quantified by counting 150
cells in 5–10 separate fields of view per slide, and noting
the percentage of apoptotic cells based on morphological
appearance, as previously described [16,17]. Percentage
treatment-induced apoptosis was computed as follows:
Caspase protease CPP32 activity
The activity of caspase protease-3 (CPP32) was deter-
mined by using a fluorescent substrate for caspase-like
proteases (Apo-Assay kit containing CPP32 specific pep-
tide, Ac-DEV-AFC, and CPP32 inhibitor, zVAD-fmk, + lys-
ing buffer: Geno Tech Inc. St. Louis MO). The cells were
preincubated with and without caspase inhibitor, z-VAD-
fmk, prior to treatment with genistein isoflavone. Cells
were then assayed for caspase protease activity. Briefly, 1 ×
103 cells/ml were seeded in triplicates in 96-well microti-
tre plates, cultured for 48 hr as previously described. Cas-
pase inhibitor, z-VAD-fmk (10 µM) was directly
dispensed into each well and incubated for 2 hr. The
supernatants were carefully aspirated and discarded; and
the cells treated with varying concentrations of genistein
(G1–70) for up to 48 hr; harvested and centrifuged at
10,000 rpm for 10 min, then resuspended in PBS. One
half of each cell suspension was processed for apoptosis
determination. The other half was centrifuged again and
the pelleted cells resuspended in hypotonic lysing buffer
on ice. After 30 min on ice cells were disrupted by passing
20 times through 27 G needle and centrifuged at 10,000
Percentapoptosis
N apoptoticcells
Totalcellscounted
o
=× 100
Growth inhibition of human adenocarcinoma cells Figure 1
Growth inhibition of human adenocarcinoma cells. Cells were grown and treated with indicated concentrations of 
cytoregR as described in the methods. Cell growth inhibition (cell death) was assessed by passage of Trypan blue dye into the 
cells, observed under microscope. The percentage of the live cells was determined by as described in the methods. A-24 hr: 
Percentage of live cells after 24 hr treatment. B-48 hr: The percentage of live cells at 48 hr treatment. The values represent 
the means +SEM of triplicates from two independent experiments. Bars = SEMJournal of Carcinogenesis 2006, 5:1 http://www.carcinogenesis.com/content/5/1/1
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rpm × 10 min. The supernatants (25 – 50µg total protein)
were incubated with caspase reagents for 2 hr at 37°C, and
substrate cleavage determined by recording the absorb-
ance at 405 nm on ELISA plate reader as previously
described [18,19] and caspase-3 (CPP32) activity was
expressed/calculated as a percentage of the positive con-
trol. In principle, the level of caspase activity in the cell
lysate is directly proportional to the color reaction; hence
to the degree of apoptosis.
Statistical analysis
The experiments were performed in triplicates and
repeated twice, to confirm similar results. Significance of
the differences in mean values was determined using the
Student's t-test and considering P < 0.05 to be statistically
significant [31]
Results
Cell growth inhibition
Cytoreg® was examined for its ability to inhibit growth
and proliferation in a panel of human cancer cells [breast
cancer cells – GI-101, MCF-7; prostate cancer cells – PC3,
LNCaP; testis cancer cells – INTERA-2 cl.D1; normal
human placenta – nPL; normal human primary testis cell
line – Hs 1.Tes]. CytoregR was added to the adherent cells
directly at dilutions of 50, 100, 200, 500, 1000, and 2000
as described in the materials. The data obtained revealed
that CytoregR induced significant dose- and time-depend-
ent inhibition of growth and proliferation in all the cells
with significant differences in chemosensitivity (P < 0.05
– P < 0.01) in the different cancer cells as summarized in
Figs 1, 2, 3 and Table 1. Difference in chemosensitivity to
cytoregR increased with exposure time, more apparent at
48 hr incubation. The Trypan blue exclusion stain indi-
cated that cell viability significantly decreased in all cell
types with increasing exposure concentration of the
Growth inhibition of human adenocarcinoma cells exposed  to cytoregR Figure 3
Growth inhibition of human adenocarcinoma cells exposed 
to cytoregR. Cells were grown and treated with indicate 
concentrations/dilutions of cytoregR as described in 
themethods. Treatment-induced cytotoxicity was assessed 
by measuring the release of lactate dehydrogenase from dead 
cells, using the LDH assay as described in the methods. The 
values/data points represent the means ± SEM of triplicates 
from two independent experiments
Growth inhibition of human adenocarcinoma cells Figure 2
Growth inhibition of human adenocarcinoma cells. Cells 
were grown and treated with cytoregR for up to 48 hr as 
described in the methods Cell viability was assessed by the 
ability of live cells to metabolically reduce MTS Cell viability 
was assessed by the ability of live cells to metabolicallyreduce 
MTS to purple formazan after treatment with cytoregR for 
48 hr. Percentage viability was determined by setting the 
absorbance of control, non-treated cells as 100%. Values rep-
resent the means + SEM of triplicates from two independent 
experiments Bars = SEM
Treatment-induced apoptosis in human adenocarcinoma cells Figure 4
Treatment-induced apoptosis in human adenocarcinoma cells 
Cells were grown and treated with indicate concentrations/
dilutions of cytoregR as described in the methods. Percent-
age of apoptosis was determined by the TUNEL DNA frag-
mentation assay as described in the methods. The values 
represent the means ± SEM of triplicates from two independ-
ent experiments.Journal of Carcinogenesis 2006, 5:1 http://www.carcinogenesis.com/content/5/1/1
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CytoregR but no significant effect on the normal cells rela-
tive to the tumor cells at the physiological pH7.1 (the
1:500 dilution) of CytoregR [Figs 1, 2, 3, 4]. Significant
negative correlations were found between LDH and MST
& Trypan blue activities (r = -.75, P < 0.01), and significant
positive correlations between MTS and Trypan blue exclu-
sion assays (r = 63, P < 0.01). These results indicate the
validity/accuracy of the data obtained. Significant treat-
ment-induced morphological changes indicative of cell
death and growth inhibition were observed in all the cells
with increasing concentration of cytoregR.
Treatment-induced apoptosis
The TUNEL DNA fragmentation analysis was used to
determine mode of cell death in growth inhibition in the
treated cells as described in the methods. Figs 4, 5 and
Table 1 revealed that CytoregR induced apoptosis as the
main mode of growth inhibition in the panel of cells stud-
ied; in a dose-dependent manner, and with significant dif-
ferences in chemosensitivity (P < 0.01) between the cells.
The normal, non-cancer cells, nPL and Hs 1.Tes testis cells,
were not significantly affected (P < 0.05) by CytoregR at
the physiological pH7.1 (1:500 dilution). However, with
increasing exposure concentrations (lower dilutions, 200
– 50) cell death due to necrosis significantly increased
concurrent with decreasing apoptotic cell death (Figs 4, 5,
Table 1). The classical characteristics of apoptosis – cell
shrinkage, nuclear condensation, formation of apoptotic
bodies-were observed in all cells (Fig 7-microphotos), to
varying degrees; indicating that growth inhibition was
predominantly due to treatment-induced apoptosis.
To determine the relationship between growth inhibition
and apoptosis induction, we correlated the percentage of
viable cells with the percentage of induced apoptosis. Fig
5 revealed that decreasing viability (increasing growth
inhibition) concurrently paralleled increasing rate of
apoptosis induction in the cells. The overall data revealed
a significant negative correlation between MTS/Trypan
blue exclusion and apoptosis induction (r = -0.67, P <
0.01).
To determine the potential involvement in the caspase
protease 3 in the molecular mechanism of CytoregR-
induced apoptosis, the cells were treated with CytoregR co-
administered with or without CPP32 inhibitor (DEVD-
fmk), and then cultured as previously described. Post-
treatment apoptosis was determined as previously
described. CytoregR induces expression of CPP32 in all
the cells with subsequent induction of apoptosis; consist-
ent with previous observations in genistein-treated cells
(Kumi-Diaka et al, NA Sanderson and Alexis Hall, 2000).
As shown in Fig 6, treatment-induced expression of cas-
pase-3 protease (CPP32) significantly correlated with
treatment-induced apoptosis in all the cells, with manifes-
tation of dose dependency on CytoregR. It was observed
that blocking of CPP32 with the caspase-3 inhibitor,
DEVD-fmk, significantly (P < 0.001) reduced apoptosis
induction in the cancerous cells; indicating the significant
role of CPP32 in the molecular pathway of CytoregR-
induced apoptosis in the panel of cells studied, consistent
with observations in other previous studies. Blocking the
expression of CPP32 did not completely stop treatment-
induced apoptosis in any cell; suggesting the existence of
an alternative or potential, caspase-independent death
pathway in CytoregR-induced apoptosis in all the cells.
Caspase protease-3 activation/expression significantly
correlated with apoptosis induction (0.78, P < 0.01).
Discussions
The battery of assays that were used in the present studies
indicates that cytoregR inhibits cell growth and prolifera-
tion in the panel of human cancer cells through induction
of apoptosis at the physiological concentration/dilution
of the drug. Growth inhibition of the tested cells strongly
correlated with the MTT, Trypan blue exclusion, and LDH
assay results. The pattern of response in all the targeted
cells was significantly similar, and consistent with results
of previous studies with genistein isoflavone [18,20,21].
The treatment-induced morphological changes observed
in all the cells (indicative of cell death, and growth inhibi-
tion) were consistent with previous observations in other
studies with other cytotoxic agents [18,22]. The inverse
correlation between the MTT and the LDH assays offers a
strong support for the reliability of the data. The overall
data demonstrate that CytoregR significantly inhibit cell
growth and proliferation through induction of apoptosis
as the main death pathway in all the cells; consistent with
previous results in with other agents [23,24]. In all the
cells, induction of apoptosis correlated inversely with
decrease cell viability, concurrent with increasing concen-
tration of cytoregR; further indicating that apoptosis was
mostly accountable for cell death and growth inhibition.
The observed bio-morphological changes indicative of
apoptosis were identical in pattern and severity in the
cells; consistent with previous results [25,26]. However,
cytoregR had no significant effect on normal, non-cancer-
ous human cells relative to the cancer cells studied. The
bio-morphological hallmarks of apoptosis observed in
the treated cells were in conformity with previous obser-
vations in apoptosis in other mammalian cancer cells
[26,27]. Similar to observations in preliminary studies,
the chemotoxic effects of cytoregR in the cells at dilutions
within physiologic (pH 7–7.2) concentrations (dilutions
of 2000, 1000, 500, 200) were selective for the cancer cells
studied; thus indicating that the differential effects of
cytoregR  on the human tumor versus normal cells is
mostly due to the chemical composition of the com-
pound and not the acidity of the compound.Journal of Carcinogenesis 2006, 5:1 http://www.carcinogenesis.com/content/5/1/1
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The potential signaling pathways in cytoregR-induced
apoptosis is under investigation presently. However, in
the present results the significant positive correlation of
CPP32 expression with percent apoptosis induction in all
the cells strongly implicates caspase-3 in the apoptosis
inducing mechanism in the cells. The observation is con-
sistent with the significant role of caspase-3 protease in
genistein-induced apoptosis in both human testis and
prostate cancer cells [18,19,21,28,29].
CytoregR induced apoptosis in both hormone-sensitive
(GI-101, LNCaP) and hormone-independent cancer cells
(PC3) to varying degrees; with significant differences in
sensitivity. Therefore cytoregR could be used in treatment
of cancer cells independently of hormonal sensitivity of
the cells. As observed in this study, since both hormone-
sensitive and hormone independent tumors were suscep-
tive to growth inhibition by cytoregR, it could be inferred
that the action of cytoregR does not appear related to hor-
mone modulation/ regulation activities, at least not
directly.
Conclusion
It is concluded from the data obtained that: i) CytoregR
exerts a dose- and time-dependent growth inhibition
effects in the panel of the cancer cells investigated, and
with significant differences (P > 0.05)in chemosensitivity
between the cells; ii) growth inhibition in cells was mostly
through the apoptosis death pathway; iii) CytoregR did
not significantly inhibit growth in the normal placenta
and testis cells studied; iv) CytoregR induces activation/
expression of CPP32 concurrent with apoptosis induction
in all the cells; thus implicating utilization of CPP32 in
the apoptosis-induction death machinery; consistent with
previous data; and v) caspase-3 protease could provide
potential target for regulation of CytoregR-induced apop-
tosis in the panel of cells investigated independent of hor-
Photomicrographic changes in human adenocarcinoma cells,  LNCaP, characteristic of apoptosis; becoming more evident  after 48 hr treatment with 1:500 dilution of cytoregR Figure 7
Photomicrographic changes in human adenocarcinoma cells, 
LNCaP, characteristic of apoptosis; becoming more evident 
after 48 hr treatment with 1:500 dilution of cytoregR. A: 
control LNCaP cells without treatment and incubatingfor 48 
hr; cells showing normal morphological characteristics of 
proliferation. B: Light photomicrograph of LNCaP cells after 
48 hr treatment; showing cell shrinkage, nuclear condensa-
tion and fragmentation -classical characteristics of apoptosis.
Correlation of % viable cells as assessed by the Trypan blue  exclusion assay and apoptosis in treated cells Figure 5
Correlation of % viable cells as assessed by the Trypan blue 
exclusion assay and apoptosis in treated cells. Percentage 
apoptotic cells was determined by the TUNEL DNA frag-
mentation assay as described. The treatment-induced reduc-
tion in viable cells corresponded with simultaneous increase 
in apoptotic cells at corresponding dilutions/concentrations 
of cytoregR. The data points represent the means ± SEM of 
triplicates from two independent experiments.
Correlation of cytoregR-induced expression of caspase-3  protease (CPP32) and apoptosis in adenocarcinoma cells Figure 6
Correlation of cytoregR-induced expression of caspase-3 
protease (CPP32) and apoptosis in adenocarcinoma cells. 
Cells were grown and treated with varying dilutions of 
cytoregR as described in the methods. Caspase-3 protease 
activation was determined by using a fluorescent substrate 
for caspase-like proteases as described in the methods. 
CPP32 expression correlated positively with percentage of 
apoptosis induction. Data points represent the means ± SEM 
of triplicates from two independent experiments.Journal of Carcinogenesis 2006, 5:1 http://www.carcinogenesis.com/content/5/1/1
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monal sensitivity of the cells. Our data show that CytoregR
is a strong inhibitor of proliferation and growth of a series
of human cancer cells, and thus supports the view that this
novel drug could play a significant role in chemothera-
peutic regimen for at least some human malignant
tumors. Preliminary in vivo animal studies and limited
human studies showed no significant side effects.
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